PPLPHARMA

Piramal Pharma Share PricePiramal Pharma

₹126.2
-0.4 (-0.32%)
As on 03 December, 2023 | 06:11 BSE: 543635 NSE: PPLPHARMAISIN: INE0DK501011

Piramal Pharma Performance

Day Range

  • Low 124.20
  • High 128.20
₹ 126.2

52 Week Range

  • Low 61.62
  • High 142.38
₹ 126.2
  • Open Price126.45
  • Previous Close126.60
  • Volume7239820

Start SIP in Piramal Pharma

Start SIP

Piramal Pharma Share Price

  • Over 1 Month 18.39%
  • Over 3 Month 21.4%
  • Over 6 Month 59.54%
  • Over 1 Year -6.32%

Piramal Pharma Key Statistics

P/E Ratio -124.9
PEG Ratio 0.8
Market Cap Cr 16,697
Price to Book Ratio 2.5
EPS 0.5
Dividend 0
Relative Strength Index 71.54
Money Flow Index 83.34
MACD Signal 5.29
Average True Range 4.68

Piramal Pharma Investment Rating

  • Master Rating:
  • Piramal Pharma has an operating revenue of Rs. 7,539.78 Cr. on a trailing 12-month basis. An annual revenue growth of 7% is good, Pre-tax margin of -2% needs improvement, ROE of -2% is poor and needs improvement. The company has a reasonable debt to equity of 50%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 18% and 39% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 15% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 52 which is a POOR score indicating inconsistency in earnings, a RS Rating of 66 which is FAIR indicating the recent price performance, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 73 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Piramal Pharma Financials
IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 9948461,0558138297461,127
Operating Expenses Qtr Cr 908830965786782813945
Operating Profit Qtr Cr 8617902747-66182
Depreciation Qtr Cr 51505347474551
Interest Qtr Cr 28343433292020
Tax Qtr Cr 19-824335-735
Net Profit Qtr Cr 77-3342-247-17151
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 3,7843,319
Operating Expenses Annual Cr 3,3462,698
Operating Profit Annual in Cr 98397
Depreciation Cr 192131
Interest Annual Cr 11654
Tax Annual Cr 5481
Net Profit Annual Cr 70343
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 72255
Cash from Investing Activity Annual Cr -435-1,223
Cash from Financing Annual Activity Cr 290906
Net Cash Flow Annual Cr -73-62
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 5,2625,067
Fixed Assets Annual Cr 3,0181,814
Total Non Current Assets Annual Cr 5,6945,250
Total Current Assets Annual Cr 2,3491,958
Total Assets Annual Cr 8,0427,208
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 4443
ROE Annual % 17
ROCE Annual % 49
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 1320
IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 1,9111,7492,1641,7161,7201,4822,131
Operating Expenses Qtr Cr 1,6461,6171,8121,6291,5471,4651,733
Operating Profit Qtr Cr 2661323518717317398
Depreciation Qtr Cr 185174184164166162165
Interest Qtr Cr 11011910495836257
Tax Qtr Cr 35-9451711-669
Net Profit Qtr Cr 5-9950-90-37-109204
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 7,3076,835
Operating Expenses Annual Cr 6,4535,609
Operating Profit Annual in Cr 628950
Depreciation Cr 677586
Interest Annual Cr 344198
Tax Annual Cr 66109
Net Profit Annual Cr -186376
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 484766
Cash from Investing Activity Annual Cr -1,339-1,812
Cash from Financing Annual Activity Cr 818794
Net Cash Flow Annual Cr -37-251
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 6,7746,697
Fixed Assets Annual Cr 7,7807,021
Total Non Current Assets Annual Cr 9,6878,730
Total Current Assets Annual Cr 4,8354,067
Total Assets Annual Cr 14,52312,797
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 5756
ROE Annual % -36
ROCE Annual % 27
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 1219

Piramal Pharma Technicals

EMA & SMA

Current Price
₹126.2
-0.4 (-0.32%)
pointer
  • Bullish Moving Average
  • ___
  • 16
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • ₹118.15
  • 50 Day
  • ₹110.29
  • 100 Day
  • ₹104.48
  • 200 Day
  • ₹102.99
  • 20 Day
  • ₹118.75
  • 50 Day
  • ₹106.52
  • 100 Day
  • ₹103.42
  • 200 Day
  • ₹90.40

Piramal Pharma Resistance and Support

PIVOT
₹126.2
Resistance
First Resistance 128.20
Second Resistance 130.20
Third Resistance 132.20
RSI 71.54
MFI 83.34
MACD Single Line 5.29
MACD 5.54
Support
First Resistance 124.20
Second Resistance 122.20
Third Resistance 120.20

Piramal Pharma Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 7,631,577 409,892,001 53.71
Week 7,197,392 323,018,964 44.88
1 Month 11,225,621 455,198,932 40.55
6 Month 8,567,232 391,608,195 45.71

Piramal Pharma Result Highlights

Piramal Pharma Synopsis

NSE-Medical-Diversified

Piramal Pharma is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 3443.22 Cr. and Equity Capital is Rs. 1193.32 Cr. for the Year ended 31/03/2023. Piramal Pharma Ltd. is a Public Limited Listed company incorporated on 04/03/2020 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is U24297MH2020PLC338592 and registration number is 338592.
Market Cap 16,697
Sales 3,709
Shares in Float 86.00
No of funds 182
Yield
Book Value 2.92
U/D Vol ratio 2.6
LTDebt / Equity 11
Alpha -0.03
Beta 1.69

Piramal Pharma

Owner NameSep-23Aug-23Jun-23Mar-23
Promoters 35.02%35.02%34.79%34.79%
Mutual Funds 3.8%3.62%0.91%0.53%
Insurance Companies 3.8%3.82%4.21%4.18%
Foreign Portfolio Investors 14.33%14.18%15.01%19.28%
Financial Institutions/ Banks
Individual Investors 16.95%16.81%16.77%13.94%
Others 26.1%26.55%28.31%27.28%

Piramal Pharma Management

Name Designation
Mrs. Nandini Piramal Chairperson
Mr. Peter DeYoung Executive Director
Mr. Vivek Valsaraj Executive Director & CFO
Mr. Neeraj Bharadwaj Non Executive Director
Mr. Nathalie Leitch Non Executive Director
Mr. S Ramadorai Independent Director
Mr. Jairaj Purandare Independent Director
Mr. Peter Stevenson Independent Director
Mr. Sridhar Gorthi Independent Director
Ms. Vibha Paul Rishi Independent Director

Piramal Pharma Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Piramal Pharma Corporate Action

Date Purpose Remarks
2023-10-27 Quarterly Results
2023-08-03 Quarterly Results
2023-05-24 Audited Results
2023-02-08 Quarterly Results & Rights issue
2022-11-08 Quarterly Results

Piramal Pharma MF Shareholding

Name Amount(cr)
ICICI Prudential Value Discovery Fund Growth 32,494
ICICI Prudential Equity & Debt Fund Growth 26,183
Quant Small Cap Fund Growth 9,521
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Growth 3,271
Tata Mid Cap Growth Fund Regular Growth 2,521

Piramal Pharma FAQs

What is Share Price of Piramal Pharma ?

Piramal Pharma share price is ₹126 As on 03 December, 2023 | 05:57

What is the Market Cap of Piramal Pharma ?

The Market Cap of Piramal Pharma is ₹16696.6 Cr As on 03 December, 2023 | 05:57

What is the P/E ratio of Piramal Pharma ?

The P/E ratio of Piramal Pharma is -124.9 As on 03 December, 2023 | 05:57

What is the PB ratio of Piramal Pharma ?

The PB ratio of Piramal Pharma is 2.5 As on 03 December, 2023 | 05:57

Q2FY23